Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBIT (2021 - 2025)

Historic EBIT for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.1 million.

  • InMed Pharmaceuticals' EBIT rose 671.73% to -$2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.9 million, marking a year-over-year decrease of 16.84%. This contributed to the annual value of -$7.9 million for FY2025, which is 304.87% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its EBIT stood at -$2.1 million for Q4 2025, which was up 671.73% from -$1.8 million recorded in Q3 2025.
  • InMed Pharmaceuticals' EBIT's 5-year high stood at -$485150.0 during Q2 2023, with a 5-year trough of -$6.5 million in Q2 2022.
  • In the last 5 years, InMed Pharmaceuticals' EBIT had a median value of -$2.1 million in 2023 and averaged -$2.5 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 9255.9% in 2023, then plummeted by 31929.53% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' EBIT stood at -$4.3 million in 2021, then surged by 48.66% to -$2.2 million in 2022, then increased by 25.7% to -$1.6 million in 2023, then crashed by 37.03% to -$2.3 million in 2024, then grew by 6.72% to -$2.1 million in 2025.
  • Its EBIT stands at -$2.1 million for Q4 2025, versus -$1.8 million for Q3 2025 and -$1.8 million for Q2 2025.